QGEN
NYSEQiagen N.V.
Price$36.45-9.98 (-21.49%)
2026-03-052026-06-08
News · 26 weeks30-20%
2025-12-142026-06-07
Mix1890d
- Dividends9(50%)
- Other4(22%)
- Analyst3(17%)
- Earnings1(6%)
- Leadership1(6%)
Latest news
25 items- SECAmendment: SEC Form SCHEDULE 13G/A filed by Qiagen N.V.SCHEDULE 13G/A - QIAGEN N.V. (0001015820) (Subject)
- PRQIAGEN Supports Infectious Disease Research and Surveillance Efforts for Bundibugyo Ebolavirus OutbreakTwo custom-designed research-use-only (RUO) QIAcuity digital PCR assays now available to target Bundibugyo ebolavirus sequences associated with the current outbreak Assays designed for integration into existing QIAcuity to support research, wastewater surveillance and analytical evaluation by qualified laboratories QIAGEN's broader Sample to Insight portfolio includes kits for sample preparation and next-generation sequencing to support outbreak research workflows QIAGEN N.V. (NYSE:QGEN, Frankfurt Prime Standard: QIA)) today announced the availability of two custom-designed research-use-only (RUO) digital PCR assays to support infectious disease research and surveillance efforts
- PRQIAGEN launches QIA Agent, connecting AI-driven scientific guidance across Sample to Insight workflowsNew AI-powered scientific platform available on www.qiagen.com connects experiment planning, product discovery and workflow support through a single conversational interface Natural-language experience helps reduce time spent searching across systems and connects customers more quickly to relevant QIAGEN information Expands QIAGEN's digital ecosystem with AI-driven workflow support embedded directly into the customer experience QIAGEN N.V. (NYSE:QGEN, Frankfurt Prime Standard: QIA)) today announced the global launch of QIA Agent, an AI-powered digital assistant designed to simplify how researchers plan experiments, identify suitable products, access technical information and man
- PRQIAGEN to advance AI-driven drug discovery with graph-based AI and curated bioinformatics knowledge with NVIDIACollaboration integrates NVIDIA accelerated computing and the NVIDIA BioNeMo platform with QIAGEN Digital Insights' curated biomedical knowledge bases Goal to advance how disease mechanisms, therapeutic targets and biomarkers are identified Graph-based AI approach designed to help researchers explore mechanisms, therapeutic targets and biomarkers with greater speed, context and confidence Initial pilot programs available to select pharmaceutical and biotechnology partners, with broader availability in future stages following validation QIAGEN (NYSE:QGEN, Frankfurt Prime Standard: QIA)) announced at the 2026 BIO-IT World Conference & Expo in Boston that the QIAGEN Digital Insigh
- PRQIAGEN to Appoint Dr. Metin Colpan as Honorary Chairman of the Supervisory Board, Continue Governance Renewal and Propose Increased Returns at 2026 Annual General MeetingCo-founder and former CEO Dr. Metin Colpan to become Honorary Chairman of the Supervisory Board after deciding not to stand for re-election Robert McMahon nominated for election to Supervisory Board as part of ongoing renewal process, with seven of eight proposed members having joined since 2021 40% increase in annual dividend proposed to $0.35 per share, reflecting continued commitment to increasing returns to shareholders Additional share repurchase authorizations, including authorization for further open-market share repurchases and a new $200 million synthetic share repurchase Thierry Bernard to stand for re-election as Managing Board member until a new CEO has been app
- PRQIAGEN Plans to Launch New Fully Automated Sample to Insight Workflow and an AI-Enabled Risk Stratification Tool to Advance QuantiFERON Latent TB TestingAmbition to support high-throughput laboratories in efficiently scaling latent tuberculosis (TB) screening as testing volumes continue to grow Fully automated workflow targeted for late 2027 launch integrates QuantiFERON test, Diasorin LIAISON systems, and purpose-built end-to-end automation from new Inpeco partnership AI-enabled risk stratification tool for TB progression targeted for late 2027 launch, designed to support all QuantiFERON customers with informed clinical decision-making for patient care QIAGEN and Diasorin driving LIAISON adoption with LIAISON QuantiFERON-TB Gold Plus II, designed to deliver significant throughput and workflow benefits in the U.S. and Europe
- PRQIAGEN Reports Full Results for Q1 2026Q1 2026 results in line with pre-announcement: Net sales rise 2% to $492 million on a reported basis, and -1% at constant exchange rates (CER) vs. outlook for at least 1% CER growth Sample technologies, QIAcuity and QDI deliver solid growth; QuantiFERON sales affected by significantly lower immigration testing demand Diluted EPS of $0.33; adjusted diluted EPS of $0.54, also $0.54 CER in line with outlook Adjusted operating income margin at 27.4%, as ongoing high level of profitability absorbs Parse investments and headwinds from tariffs and currency movements Updated full-year 2026 outlook reconfirmed: Net sales growth of about 1-2% CER and adj. diluted EPS of at least $2.
- ANALYSTQiagen upgraded by Robert W. Baird with a new price targetRobert W. Baird upgraded Qiagen from Neutral to Outperform and set a new price target of $43.00
- PRQIAGEN reports preliminary Q1 2026 results: achieves adjusted EPS outlook with mixed sales trends; updates full-year 2026 outlookSample technologies, QIAcuity and QDI deliver solid growth; QuantiFERON sales affected by significantly lower immigration testing demand QIAGEN N.V. (NYSE:QGEN, Frankfurt Prime Standard: QIA)) today announced preliminary results for the first quarter of 2026, continuing to deliver strong profitability as adjusted diluted earnings per share (EPS) achieved the outlook. Sales trends were mixed, as lower QuantiFERON sales and cautious U.S. Life Sciences customer demand offset solid growth in other areas of the portfolio. For Q1 2026, preliminary net sales were $492 million, up 2% on a reported basis and down 1% at constant exchange rates (CER) compared with the outlook for at least 1% CER g
- PRQIAGEN to Showcase New Sample to Insight Solutions for Complex Oncology Applications at AACR 2026Highlights solutions addressing key oncology research needs across automated sample preparation, single-cell analysis, genomic profiling and data analysis QIAsymphony Connect will serve as a foundation for lab workflows, enabling standardized nucleic acid extraction for clinical and translational research Introduction of the QIAGEN Discovery Platform, an AI-grounding solution to power downstream AI applications and support drug discovery for research purposes QIAGEN N.V. (NYSE:QGEN, Frankfurt Prime Standard: QIA)) today announced it will showcase its oncology workflow applications at the American Association for Cancer Research (AACR) Annual Meeting 2026 in San Diego, demonstrat
- PRQIAGEN Expands Into Bloodstream Infection Syndromic Testing With New Rapid QIAstat-Dx PanelQIAstat-Dx BCID GPF Plus AMR Panel detects gram-positive bacteria, fungi and key antimicrobial resistance markers from positive blood cultures and colonies CE-IVDR-certified panel identifies 20 pathogens and 10 resistance targets in about one hour to enable faster clinical decision-making Launch marks QIAGEN's expansion into bloodstream infection syndromic testing, building on earlier panels for respiratory, gastrointestinal and meningitis / encephalitis testing QIAGEN N.V. (NYSE:QGEN, Frankfurt Prime Standard: QIA)) today announced its expansion into syndromic testing for bloodstream infections with the launch of the CE-IVDR-certified QIAstat-Dx BCID GPF Plus AMR Panel. The lau
- ANALYSTQiagen downgraded by Barclays with a new price targetBarclays downgraded Qiagen from Overweight to Equal Weight and set a new price target of $44.00
- PRQiagen Announces Form 20-F Annual Report Filing for 2025 ResultsQIAGEN N.V. (NYSE:QGEN, Frankfurt Prime Standard: QIA)) announced today that it has filed its annual report, including its audited consolidated financial statements on Form 20-F, for the year ended December 31, 2025, with the U.S. Securities and Exchange Commission. The document can be accessed on QIAGEN's website here. QIAGEN will provide printed copies of the 2025 Annual Report to shareholders free of charge upon request. To obtain a printed copy of the 2025 Annual Report please use our contact form or send an email to ir@qiagen.com. About QIAGEN QIAGEN N.V., a Netherlands-based holding company, is a global leader in Sample to Insight solutions that enable customers to extract and a
- SECSEC Form 20-F filed by Qiagen N.V.20-F - QIAGEN N.V. (0001015820) (Filer)
- SECSEC Form IRANNOTICE filed by Qiagen N.V.IRANNOTICE - QIAGEN N.V. (0001015820) (Filer)
- PRQIAGEN Highlights Newly Published Data Supporting Efficacy of QuantiFERON for TB PreventionNew study supports QuantiFERON-TB Gold Plus use in immunocompromised and other high-risk populations in various settings Findings show QuantiFERON testing is cost-effective compared with tuberculin skin testing in people living with HIV CPD-accredited online QuantiFERON World TB Day program on March 24 convenes global experts to advance TB detection, prevention and high-impact scientific exchange QIAGEN N.V. (NYSE:QGEN, Frankfurt Prime Standard: QIA)) today announced newly published clinical and health economic data supporting the use of its QuantiFERON-TB Gold Plus (QFT-Plus) blood test for detecting tuberculosis (TB) infection, particularly in immunocompromised and other high-ri
- ANALYSTQiagen upgraded by Deutsche Bank with a new price targetDeutsche Bank upgraded Qiagen from Hold to Buy and set a new price target of $54.00
- PRQIAGEN Receives U.S. Clearance for Gastrointestinal Panels on Fully Automated QIAstat-Dx Rise Syndromic Testing SystemFDA clears Gastrointestinal (GI) Panels for use on the fully automated QIAstat-Dx Rise platform, marking the ninth U.S. QIAstat-Dx panel clearance in last 24 months Laboratories can now run respiratory and gastrointestinal panels, including comprehensive and Mini panels, on one scalable automated system QIAstat-Dx Rise delivers higher-throughput automation for up to 160 tests per day with minimal hands-on time while supporting urgent sample prioritization QIAGEN N.V. (NYSE:QGEN, Frankfurt Prime Standard: QIA)) today announced that the U.S. Food and Drug Administration (FDA) has cleared the use of all QIAstat-Dx® Gastrointestinal (GI) Panels on the QIAstat-Dx Rise automated syndrom
- PRParse Biosciences Launches Evercode Whole Transcriptome V4 With Shorter Workflow, Higher Sensitivity and Higher Cell RecoveryNew chemistry reduces barriers to scaling single-cell studies across research settings Launch planned for March 2026, available across Evercode Whole Transcriptome product line Parse Biosciences, a QIAGEN company (NYSE:QGEN, Frankfurt Prime Standard: QIA)), and the leading provider of scalable and accessible single-cell sequencing solutions today announced the launch of the new Evercode™ Whole Transcriptome v4 product line, delivering expanded scalability, higher sensitivity and a simplified workflow for single-cell RNA sequencing. Evercode v4 supports extraordinary scalability of up to five million cells and 384 samples in a single run, enabling researchers to design large studies
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Qiagen N.V.SCHEDULE 13G/A - QIAGEN N.V. (0001015820) (Subject)
- SECSEC Form 6-K filed by Qiagen N.V.6-K - QIAGEN N.V. (0001015820) (Filer)
- PRQIAGEN Exceeds Q4 2025 Outlook Driven by Growth PillarsQ4 2025: Net sales of $540 million (+4% at actual rates, +1% at constant exchange rates (CER)); diluted EPS of $0.49 and adjusted diluted EPS of $0.62 Net sales growth of 1% CER ahead of outlook for steady results vs. Q4 2024, adjusted diluted EPS of $0.62 CER ahead of outlook of about $0.60 CER FY 2025: Net sales of $2.09 billion (+6% at actual rates, +5% CER) at high end of outlook for 4-5% CER growth, adj. diluted EPS of $2.40 CER ahead of outlook of about $2.38 CER Growth pillars on target and deliver $1.49 billion CER of sales with 8% CER growth Adjusted operating income margin at 29.5%, rises 80 basis points from 2024 despite tariffs and currency headwinds 2026 out
- PRQIAGEN Showcases QIAsprint Connect High-Throughput Automation System for Labs Worldwide at SLAS 2026QIAsprint Connect marks entry into high-throughput sample processing, enabling labs to scale workflows with flexible protocols, compact design and sustainability-focused features QIAGEN also to showcase new automation systems: QIAsymphony Connect for clinical applications and QIAmini for accessible low-throughput sample processing QIAGEN N.V. (NYSE:QGEN, Frankfurt Prime Standard: QIA)) today announced the first public showcase of QIAsprint Connect at SLAS 2026 in Boston, marking QIAGEN's entry into high-throughput benchtop automation for sample processing in research laboratories. QIAsprint Connect is designed to help labs process large batches of samples efficiently while retaini
- PRQIAGEN Appoints Mark Stevenson to Supervisory BoardQIAGEN (NYSE:QGEN, Frankfurt Prime Standard: QIA)) today announced that Mark Stevenson has been appointed as an independent member of the Supervisory Board as of January 23, 2026, and will stand for election at the next Annual General Meeting in June 2026. In addition, Prof. Dr. Ross Levine has stepped down from the Supervisory Board also on January 23, 2026, following his appointment to a new leadership role as Chief Scientific Officer at Memorial Sloan Kettering Cancer Center. He will continue to serve as Chair of the QIAGEN Scientific Advisory Board. "We are pleased to welcome Mark Stevenson to our Supervisory Board," said Stephen H. Rusckowski, Chairman of the Supervisory Board. "Ma
- ANALYSTQiagen downgraded by Deutsche Bank with a new price targetDeutsche Bank downgraded Qiagen from Buy to Hold and set a new price target of $54.00
QGEN FAQ
7 questionsWhat does Qiagen N.V. do?
QIAGEN N.V. provides sample to insight solutions that transform biological materials into molecular insights worldwide. The company offers primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid...Where does QGEN stock trade?
Qiagen N.V. (QGEN) is listed on NYSE.What sector and industry is QGEN in?
Qiagen N.V. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.When did Qiagen N.V. go public?
Qiagen N.V. (QGEN) completed its IPO in 2026.What are analysts saying about QGEN?
Qiagen N.V. has had 8 recent analyst actions on file. The most recent action was from Robert W. Baird: Outperform with a $4300.00 price target on 2026-04-29. Recent price targets range from $4200.00 to $4400.00.What companies are similar to QGEN?
Notable peers in the same industry include TMO (Thermo Fisher Scientific Inc), ILMN (Illumina Inc.), BIO (Bio-Rad Laboratories Inc.). Compare QGEN side-by-side with any of them on Quantisnow.How can I track QGEN on Quantisnow?
Quantisnow aggregates Qiagen N.V.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow QGEN to receive live email and push alerts on every new disclosure.